Paris, June 21th 2010 - Bryan, Garnier & Co (“Bryan Garnier”), the independent pan-European investment bank focused on growth companies, today announces the successful closing of the initial public offering in the form of ordinary shares for Integragen (Isin: FR0010908723 – Mnemo: ALINT) following a private placement targeted at qualified investors. Bryan Garnier was the sole lead manager and the sole bookrunner for this transaction.
Through this private placement, IntegraGen has raised €6.7m, with 800.149 new shares issued at an offer price of €8.40 per share (including issuance premium) representing more than 21% of IntegraGen’s capital post-deal. The Company’s share capital is now composed of 3,771,471 shares.
The proceeds raised in the private placement will allow the company to develop new generations of molecular diagnostic products and services and in particular, a new version of the predictive test for autism suspiscion.
IntegraGen is a pioneer in the development of molecular diagnostic products and services – the most dynamic segment of the in-vitro diagnostic market. In partnership with Transgenomic molecular diagnostics CLIA certified laboratory, in early June 2010, in the USA, its first genetic test was launched in the USA to evaluate the risk of autism within families with one child already suffering from autism. This test is unique as today’s diagnosis of autism is based quasi-exclusively on behavioural tests for children assumed to be autistic.
In the oncology area, in November 2009, IntegraGen signed a partnership with bioMerieux and AP-HP (Assistance Publique – Hôpitaux de Paris) to create a laboratory unit specialising in molecular diagnosis. Moreover, in 2009, IntegraGen recorded €2.7m in revenues from its genomic services to academic institutions and pharma companies.
Catherine Trividic, Healthcare Director at Bryan, Garnier & Co stated: “We usually work on capital raisings for growth companies like Integragen and once more this successful transaction demonstrates our close relationships with international investors and the ability of our experienced investment bankers to provide advice and deliver solutions to our clients”
Following a string of capital market operations since the beginning of 2009, this transaction confirms the leadership of Bryan, Garnier & Co with regards to the financing and capital raising of European growth companies. Since 1998, Bryan, Garnier & Co has successfully led more than 50 fundraisings for growth companies, having raised several hundred million Euros over the past few years thanks to an experienced team of investment bankers and sector specialists, who share with the bank’s clients their insightful knowledge of new technologies and capital markets.
Bernard Courtieu, CEO of Inetgragen, added, “We are very pleased with our Company’s successful listing which has allowed us to raise up to €6.7m from Tier I qualified investors. Bryan Garnier’s industry expertise and level of commitment have been critical for the success of this IPO in the current context of capital market instability.”
For more information please contact:
Catherine Trividic | Director – Corporate Finance / +33 1 56 68 75 05 | ctrividic @bryangarnier.com
Christian Finan | Director – Equity Capital Markets / +33 1 56 68 75 30 | firstname.lastname@example.org
About Integragen (www.integragen.fr)
Located in the Evry Genopole and created in 2000, IntegraGen is dedicated to research and identification of genetic biomarkers, development and distribution of molecular diagnostic products and services.
Through the leverage of its unique Intellectual Property and research expertise, IntegraGen’s strategy is to provide clinicians with new personalised diagnostic tools, treatments and therapies, for targeted pathologies such as autism and certain forms of cancer.
Integragen’s Business Genomic Services Unit also provides genomic services for scientific research.
About Bryan, Garnier & Co (www.bryangarnier.com)
Bryan, Garnier & Co is an independent investment bank specialising in European TMT, Healthcare and Renewable Energies growth companies. Bryan, Garnier & Co is positioned in three activities: Equity Research & Brokerage, Asset Management and Corporate Finance.
With more than 100 professionals based in London, Paris and Geneva, Bryan, Garnier & Co. combines the range of services and the expertise of top-tier investment banks with the level of attention to clients of a boutique.
The Corporate Finance department of Bryan, Garnier & Co advises European privately or publicly-owned companies, entrepreneurs and financial investors in the following transactions:
§ Equity Capital Markets transactions
§ Private Placements
§ Mergers & Acquisitions
Over the past 10 years, Bryan, Garnier & Co has become a specialist as a reference point vis-à-vis venture capital funds and feed capital funds for cross-border Private Placements in technology companies.